Budget Impact Modeling for a Single-Tablet Formulation of Ibuprofen and Famotidine for Prevention of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis and/or Rheumatoid Arthritis

Clinical Therapeutics

Volumn 35, Issue 3, 2013, Pages 321-332

  Kuan, Renee ^a   Holt, Robert J ^b   Johnson, Kenneth E ^b   Kent, Jeffrey D ^c   Peura, David A ^d   Malone, Dan ^e  

^a PriceSpective   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Horizon Therapeutics   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adherence; Budget impact model; Gastroprotection; H2 receptor antagonist; Medication cost avoidance; NSAID

Indexed keywords

FAMOTIDINE; IBUPROFEN;

ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG FORMULATION; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; UNITED STATES; UPPER GASTROINTESTINAL TRACT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; DRUG COMBINATIONS; DRUG COSTS; FAMOTIDINE; HUMANS; IBUPROFEN; MODELS, ECONOMIC; OSTEOARTHRITIS; PATIENT COMPLIANCE; STOMACH ULCER; TABLETS;

EID: 84874995477     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.02.008     Document Type: Article

References (64)

1. Wolters Kluwer prescription database 2009.
2. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
3. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006, 47(Suppl 1):S60-S66.
4. Goldstein J.L. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis?. Eur J Gastroenterol Hepatol 2000, 12(Suppl 1):S11-S15.
5. Lanza F.L., Chan F.K., Quigley E.M. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
6. Schoen R.T., Vender R.J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989, 86:449-458.
7. Wagner K.A., Nandi J., King R.L., Levine R.A. Effects of nonsteroidal antiinflammatory drugs on ulcerogenesis and gastric secretion in pylorus-ligated rat. Dig Dis Sci 1995, 40:134-140.
8. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000, 43:1905-1915.
9. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002, 46:328-346.
10. Goldstein J.L., Howard K.B., Walton S.M., et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:1337-1345.
11. Laine L., Connors L., Griffin M.R., et al. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther 2009, 30:767-774.
12. Moore R.A., Derry S., Phillips C.J., McQuay H.J. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006, 7:79.
13. Sturkenboom M.C., Burke T.A., Tangelder M.J., et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003, 18:1137-1147.
14. van Soest E.M., Sturkenboom M.C., Dieleman J.P., et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007, 26:265-275.
15. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
16. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
17. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
18. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727-734.
19. Vimovo (naproxen and esomeprazole magnesium) [prescribing information] 2011, AstraZeneca, Wilmington, DE.
20. Laine L., Maller E.S., Yu C., Quan H., Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004, 127:395-402.
21. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002, (4). CD002296.
22. Vestergaard P., Rejnmark L., Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76-83.
23. Eom C.S., Park S.M., Myung S.K., et al. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2011, 9:257-267.
24. Yu E.W., Bauer S.R., Bain P.A., Bauer D.C. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011, 124:519-526.
25. FDA Drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitors drugs (PPIs) US Food and Drug Administration, In: Administration UFaD, ed2011, Accessed February 27, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm.
26. Proton pump inhibitor class labeling change on long term and multiple daily dose PPI associated increase risk of osteoproosis-related fractures of the hip, wrist, or spine In: Administration UFaD, ed2011, Accessed February 27, 2013. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm.
27. FDA Drug safety communication: methotrexate and PPI safety information US Food and Drug Administration, In: Administration UFaD, ed 2011, Accessed February 27, 2013. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm284421.htm.
28. Weinblatt M.E., Genovese M.C., Kivitz A.J., et al. Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials. Arthritis Rheum 2010, 62(Suppl 10):S391-S392.
29. Ong C.K., Lirk P., Tan C.H., Seymour R.A. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007, 5:19-34.
30. Hudson N., Taha A.S., Russell R.I., et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997, 112:1817-1822.
31. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996, 334:1435-1439.
32. Tidmarsh G., Rodriguez S.B. Famotidine (FAM) administered orally three times daily produces better gastric acid suppression and control than does twice daily (BID) administration of the same total daily dose. Gastroenterology 2009, 136:A612.
33. Ko C.W., Deyo R.A. Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease. J Gen Intern Med 2000, 15:400-410.
34. Elliott R.A., Hooper L., Payne K., et al. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?. Rheumatology (Oxford) 2006, 45:606-613.
35. Quartero A.O., Numans M.E., Post M.W., et al. One-year prognosis of primary care dyspepsia: predictive value of symptom pattern, Helicobacter pylori and GP management. Eur J Gastroenterol Hepatol 2002, 14:55-60.
36. Talley N.J., Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005, 100:2324-2337.
37. Wilcox C.M., Cryer B., Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005, 32:2218-2224.
38. Ladabaum U., Chey W.D., Scheiman J.M., Fendrick A.M. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. Aliment Pharmacol Ther 2002, 16:1491-1501.
39. Maetzel A., Ferraz M.B., Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998, 41:16-25.
40. Schiff M., Peura D. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol 2012, 6:25-35.
41. DUEXIS [prescribing information] 2011, Horizon Pharma USA, Inc, Deerfield, IL.
42. Garcia Rodriguez L.A., Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001, 12:570-576.
43. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000, 343:834-839.
44. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007, 102:507-515.
45. Lin K.J., Hernandez-Diaz S., Garcia Rodriguez L.A. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011, 141:71-79.
46. Ray W.A., Chung C.P., Stein C.M., et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 2007, 133:790-798.
47. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999, 56:18-24.
48. Naesdal J., Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006, 29:119-132.
49. Cryer B.L., Wilcox C.M., Henk H.J., et al. The economics of upper gastrointestinal bleeding in a US managed-care setting: a retrospective, claims-based analysis. J Med Econ 2010, 13:70-77.
50. Lanas A., Garcia-Tell G., Armada B., Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 2011, 9:38.
51. Cryer B., Bhatt D.L., Lanza F.L., et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 2011, 106:272-277.
52. Niv Y., Battler A., Abuksis G., et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 2005, 50:78-80.
53. Goldstein J.L., Lowry S.C., Lanza F.L., et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2006, 23:1489-1498.
54. Yeomans N.D., Lanas A.I., Talley N.J., et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005, 22:795-801.
55. Hernandez-Diaz S., Garcia Rodriguez L.A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006, 4:22.
56. Moukarbel G.V., Signorovitch J.E., Pfeffer M.A., et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009, 30:2226-2232.
57. Tamura A., Murakami K., Kadota J. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM 2011, 104:133-139.
58. Sorensen H.T., Mellemkjaer L., Blot W.J., et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000, 95:2218-2224.
59. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996, 348:1413-1416.
60. Kripalani S., Yao X., Haynes R.B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007, 167:540-550.
61. McDonald H.P., Garg A.X., Haynes R.B. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002, 288:2868-2879.
62. van Dulmen S., Sluijs E., van Dijk L., et al. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res 2007, 7:55.
63. van Sosest E.M., Valkhof V.E., Mazzaglia G., et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011, 60:1650-1659.
64. Bandolier, Evidence-Based Thinking About Health Care. Oxford League table of analgesics in acute pain, 2007 Accessed October 17, 2012. http://www.medicine.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/Leagtab.html.